Aldose reductase (AR) has been a long-standing target for treating diabetic complications, but its structural similarity to related enzymes has made selective inhibition difficult. Off-target binding ...
Researchers from ICTER have developed a fragment-based drug discovery method combined with microcrystal electron diffraction to design enzyme inhibitors at atomic resolution. The approach aims to ...
Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...
The ICMR-National Institute of Nutrition has developed a poly-herbal extract that goes beyond blood sugar control to target complications linked to diabetes and obesity, including kidney damage, ...
CAMBRIDGE, England & DETROIT--(BUSINESS WIRE)--Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: ...
Objective— Aldose reductase (AR) is the rate-limiting enzyme of the polyol pathway. In diabetes, it is related to microvascular complications. We discovered AR expression in foam cells by gene chip ...
Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 ...
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; “Applied”), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare ...
Abstract: Hyperglycemia and reduced insulin actions affect many biological processes. One theory is that aberrant metabolism of glucose via several pathways including the polyol pathway causes ...
Applied Therapeutics has yet to confirm whether the study, posted on Clinicaltrials.gov on Thursday, means it has indeed aligned with the FDA on govorestat’s development. Applied Therapeutics has ...
What if the sugar we consume, or even the sugar our own bodies produce, could increase the risk of cancer? That’s the question driving groundbreaking research by Hyeyoung Nam, Ph.D., instructor in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results